{"entity":{"id":"da-bn-trial-exclusion","kind":"bottleneck","name":"Trial populations that skip mixed disease","aka":[],"tldr":"Antibody trials largely enrolled people with biomarker-supported Alzheimer’s disease and excluded much mixed, vascular, and diverse disease.","summary":"When a person has mixed pathology, atrial fibrillation, or anticoagulation, the trial result may not apply. Inclusive protocols are a proposed fix, not current practice everywhere.","asOf":"2026-09-21","links":[{"label":"CLARITY AD registry","url":"https://clinicaltrials.gov/study/NCT03887455"}],"tags":["dementia-atlas"],"related":[],"cancers":["alzheimers-disease","mixed-dementia"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"stage":"trials","severity":"major","metrics":[{"label":"Failure example on this atlas","value":"ENGAGE primary endpoint not met","source":"ClinicalTrials.gov NCT02477800","url":"https://clinicaltrials.gov/study/NCT02477800"}],"causes":["Strict amyloid and MRI criteria.","Under-enrolment of minoritised groups.","Exclusion of common comorbidities."],"currentEfforts":["Broader phase 4 and registry follow-up after approval."],"successLooksLike":"Label-relevant evidence includes the people who actually present to clinic."},"route":"/bottlenecks/da-bn-trial-exclusion/","neighbours":{"cancer":[{"id":"alzheimers-disease","kind":"cancer","name":"Alzheimer’s disease","route":"/diagnoses/alzheimers-disease/"},{"id":"mixed-dementia","kind":"cancer","name":"Mixed dementia","route":"/diagnoses/mixed-dementia/"}],"idea":[{"id":"da-idea-inclusive-anti-amyloid-trials","kind":"idea","name":"Antibody trials that enrol mixed and comorbid disease","route":"/ideas/da-idea-inclusive-anti-amyloid-trials/"}]}}